Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

YAN JI

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1225355829
CMS profile
1381109
Location
SAINT PAUL, MN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$88,182.38

77 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

By paying entity

PY2025 · entire year · sorted by reported total

Page 2 of 2; records 51–77 of 77 matching records. This page contains 27 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

YAN JI

NPI 1225355829 · CMS profile ID 1381109

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

SAINT PAUL, MN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–77 of 77 matching records. This page contains 27 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1225355829?year=2025&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
YAN JI, NPI 1225355829, CMS profile ID 1381109. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–77 of 77 matching records. This page contains 27 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1225355829?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). YAN JI, NPI 1225355829, CMS profile ID 1381109. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–77 of 77 matching records. This page contains 27 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1225355829?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
YAN JI, NPI 1225355829, CMS profile ID 1381109, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–77 of 77 matching records. This page contains 27 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1225355829?year=2025&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

77 matching records · $88,182.38 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 77 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–77 of 77.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Merck Sharp & Dohme LLC $558.3607/24/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1238008504 CMS
Merck Sharp & Dohme LLC $70.2807/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238029584 CMS
AstraZeneca Pharmaceuticals LP $1,675.0007/16/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1206500234 CMS
AstraZeneca Pharmaceuticals LP $670.0007/16/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1206647989 CMS
AstraZeneca Pharmaceuticals LP $3,015.0007/01/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1206382680 CMS
AstraZeneca Pharmaceuticals LP $2,345.0007/01/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1207025374 CMS
AstraZeneca Pharmaceuticals LP $2,010.0006/24/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1206495578 CMS
Janssen Biotech, Inc. $35.8106/11/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1174915569 CMS
Janssen Biotech, Inc. $49.9106/11/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1174915621 CMS
Janssen Biotech, Inc. $15.3006/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174915699 CMS
Janssen Biotech, Inc. $2,220.0006/11/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1174915884 CMS
Janssen Scientific Affairs, LLC $880.0005/27/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1174174729 CMS
Novartis Pharmaceuticals Corporation $1,650.0005/20/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1200264650 CMS
Janssen Biotech, Inc. $142.5005/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174915718 CMS
Janssen Biotech, Inc. $283.8605/07/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1174915830 CMS
Janssen Biotech, Inc. $446.9705/07/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1174915915 CMS
Deciphera Pharmaceuticals Inc. $1,650.0005/01/2025 Honoraria No dispute reported Delay: No
Change: NEW
06/30/2026 1235959666 CMS
Deciphera Pharmaceuticals Inc. $62.3605/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1235959668 CMS
Deciphera Pharmaceuticals Inc. $64.9205/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1235959670 CMS
Deciphera Pharmaceuticals Inc. $26.7005/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1235959672 CMS
Deciphera Pharmaceuticals Inc. $37.0005/01/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1235959674 CMS
Tempus AI, Inc $150.8704/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1250347285 CMS
Takeda Pharmaceuticals U.S.A., Inc. $2,040.0003/11/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1223786767 CMS
Daiichi Sankyo Inc. $1,387.5002/19/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1197037851 CMS
Amgen Inc. $2,100.0001/23/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1226908386 CMS
E.R. Squibb & Sons, L.L.C. $1,775.0001/21/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1184672769 CMS
AstraZeneca Pharmaceuticals LP $2,010.0001/14/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1206249526 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2020 $19.42 1
PY2022 $5,665.43 9
PY2023 $25,524.33 20
PY2024 $44,946.78 43
PY2025 $88,182.38 77

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2020, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2020 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $2,962,135.55 200
PY2024 Recipient $4,470.00 3
PY2024 Principal investigator $1,653,423.98 204
PY2023 Principal investigator $717,665.96 73
PY2022 Principal investigator $534,216.28 16
PY2021 Principal investigator $311,490.01 4

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

200 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $10,923.52 12/31/2025 Non-covered Recipient Entity
Metro-Minnesota Community Clinical Oncology
MK-5684-003# A Phase 3 Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer mCRPC Previously Treated With Next-generation Hormonal Agent NHA No dispute reported 06/30/2026 1232929167
Principal investigator 1 Janssen Research & Development, LLC $4,000.00 12/22/2025 Non-covered Recipient Entity
HEALTHPARTNERS INSTITUTE
A Phase 3 Randomized Study Comparing Talquetamab in Combination with Pomalidomide (Tal-P), Talquetamab in Combination with Teclistamab (Tal-Tec), and Investigator's Choice of Either Elotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pomalidomide, Bortezomib, and Dexamethasone (PVd) in Participants with Relapsed or Refractory Myeloma who Have Received 1 to 4 Prior Lines of Therapy Including an Anti-CD38 Antibody and Lenalidomide No dispute reported 06/30/2026 1175365447
Principal investigator 1 Janssen Research & Development, LLC $6,300.00 12/22/2025 Non-covered Recipient Entity
HEALTHPARTNERS INSTITUTE
A Phase 3 Randomized Study Comparing Talquetamab in Combination with Pomalidomide (Tal-P), Talquetamab in Combination with Teclistamab (Tal-Tec), and Investigator's Choice of Either Elotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pomalidomide, Bortezomib, and Dexamethasone (PVd) in Participants with Relapsed or Refractory Myeloma who Have Received 1 to 4 Prior Lines of Therapy Including an Anti-CD38 Antibody and Lenalidomide No dispute reported 06/30/2026 1175365455
Principal investigator 1 Astellas Pharma Global Development $2,618.00 12/19/2025 Non-covered Recipient Entity
HEALTHPARTNERS INSTITUTE.
A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer (LUCERNA) No dispute reported 06/30/2026 1234183089
Principal investigator 1 Genentech, Inc. $237.00 12/18/2025 Non-covered Recipient Entity
Metro Minnesota Community Oncology Research Consortium-MMCOrc
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211625145
Principal investigator 1 Genentech, Inc. $500.00 12/18/2025 Non-covered Recipient Entity
Metro Minnesota Community Oncology Research Consortium-MMCOrc
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211625156
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $3,475.00 12/15/2025 Non-covered Recipient Entity
Healthpartners Institute For Education And Research
A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) vs Epoetin Alfa for the Treatment of Anemia Due to Revised International Prognostic Scoring System (IPSS-R) Very Low, Low, or Intermediate Risk Myelodysplastic Syndrome (MDS) in Erythropoiesis-Stimulating Agent (ESA)-naive Participants who are Non-Transfusion Dependent (NTD): The ELEMENT-MDS Trial No dispute reported 06/30/2026 1235996951
Principal investigator 1 Genentech, Inc. $365.00 12/04/2025 Non-covered Recipient Entity
Metro Minnesota Community Oncology Research Consortium-MMCOrc
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211625149
Principal investigator 1 Genentech, Inc. $1,583.00 12/01/2025 Non-covered Recipient Entity
Metro Minnesota Community Oncology Research Consortium-MMCOrc
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211625153
Principal investigator 1 PFIZER INC. $21,998.34 12/01/2025 Non-covered Recipient Entity
Metro Minnesota Community Oncology Research Consortium
AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228718285
Principal investigator 1 Genentech, Inc. $5,992.00 11/26/2025 Non-covered Recipient Entity
HEALTHPARTNERS INSTITUTE
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211612463
Principal investigator 1 PFIZER INC. $21,998.34 11/26/2025 Non-covered Recipient Entity
Metro Minnesota Community Oncology Research Consortium
AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228716919
Principal investigator 1 PFIZER INC. $945.00 11/26/2025 Non-covered Recipient Entity
HEALTHPARTNERS INSTITUTE FOR
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228807867
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $750.00 11/25/2025 Non-covered Recipient Entity
HEATLHPARTNERS INSTITUTE
EMERGE 402: Phase IV Observational Study to Collect Safety and Outcome Data in Real-World Setting in Adult Patients With Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Zepzelca No dispute reported 06/30/2026 1233739923
Principal investigator 1 PFIZER INC. $800.00 11/25/2025 Non-covered Recipient Entity
HEALTHPARTNERS INSTITUTE FOR
AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228807210
Principal investigator 1 PFIZER INC. $37,632.15 11/25/2025 Non-covered Recipient Entity
HEALTHPARTNERS INSTITUTE FOR
AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228807216
Principal investigator 1 PFIZER INC. $1,600.00 11/25/2025 Non-covered Recipient Entity
HEALTHPARTNERS INSTITUTE FOR
AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228807223
Principal investigator 1 PFIZER INC. $4,000.00 11/25/2025 Non-covered Recipient Entity
HEALTHPARTNERS INSTITUTE FOR
AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228807320
Principal investigator 1 PFIZER INC. $14,400.00 11/25/2025 Non-covered Recipient Entity
HEALTHPARTNERS INSTITUTE FOR
AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228807423
Principal investigator 1 PFIZER INC. $4,800.00 11/25/2025 Non-covered Recipient Entity
HEALTHPARTNERS INSTITUTE FOR
AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228807430
Principal investigator 1 PFIZER INC. $1,000.00 11/25/2025 Non-covered Recipient Entity
HEALTHPARTNERS INSTITUTE FOR
AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228807504
Principal investigator 1 PFIZER INC. $12,544.05 11/25/2025 Non-covered Recipient Entity
HEALTHPARTNERS INSTITUTE FOR
AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228807670
Principal investigator 1 PFIZER INC. $800.00 11/25/2025 Non-covered Recipient Entity
HEALTHPARTNERS INSTITUTE FOR
A PHASE 2 BASKET STUDY OF DISITAMAB VEDOTIN IN ADULT SUBJECTS WITH PREVIOUSLY TREATED LOCALLYADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS THAT EXPRESS HER2 No dispute reported 06/30/2026 1228807764
Principal investigator 1 PFIZER INC. $6,000.00 11/25/2025 Non-covered Recipient Entity
HEALTHPARTNERS INSTITUTE FOR
AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228807771
Principal investigator 1 PFIZER INC. $4,800.00 11/25/2025 Non-covered Recipient Entity
HEALTHPARTNERS INSTITUTE FOR
AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228807776
Principal investigator 1 PFIZER INC. $20,504.00 11/25/2025 Non-covered Recipient Entity
HEALTHPARTNERS INSTITUTE FOR
AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228807861
Principal investigator 1 BeOne Medicines Ltd. $500.00 11/20/2025 Non-covered Recipient Entity
HealthPartners Institute
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190334476
Principal investigator 1 Astellas Pharma Global Development $2,783.00 11/14/2025 Non-covered Recipient Entity
HEALTHPARTNERS INSTITUTE.
A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer (LUCERNA) No dispute reported 06/30/2026 1234183087
Principal investigator 1 PFIZER INC. $21,998.34 11/12/2025 Non-covered Recipient Entity
Metro Minnesota Community Oncology Research Consortium
AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228716747
Principal investigator 1 PFIZER INC. $10,940.00 11/12/2025 Non-covered Recipient Entity
Metro Minnesota Community Oncology Research Consortium
AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228717169
Principal investigator 1 PFIZER INC. $21,998.34 11/12/2025 Non-covered Recipient Entity
Metro Minnesota Community Oncology Research Consortium
AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228718671
Principal investigator 1 PFIZER INC. $10,940.00 11/12/2025 Non-covered Recipient Entity
Metro Minnesota Community Oncology Research Consortium
AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228718761
Principal investigator 1 Novartis Pharmaceuticals Corporation $65,412.87 11/10/2025 Covered Recipient Teaching Hospital
Regions Hospital
A Phase IIIb, Multi-center, Open-label, Randomized Study of Tolerability and Efficacy of Oral Asciminib Versus Nilotinib in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase No dispute reported 06/30/2026 1190297873
Principal investigator 1 PFIZER INC. $3,200.00 11/10/2025 Non-covered Recipient Entity
HEALTHPARTNERS INSTITUTE FOR
A PHASE 2 BASKET STUDY OF DISITAMAB VEDOTIN IN ADULT SUBJECTS WITH PREVIOUSLY TREATED LOCALLYADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS THAT EXPRESS HER2 No dispute reported 06/30/2026 1228807315
Principal investigator 1 PFIZER INC. $4,830.00 11/10/2025 Non-covered Recipient Entity
HEALTHPARTNERS INSTITUTE FOR
AN OPENLABEL RANDOMIZED CONTROLLED PHASE 3 STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB VERSUS CHEMOTHERAPY IN SUBJECTS WITH PREVIOUSLY UNTREATED LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA THAT EXPRESSES HER2 IHC 1 AND GREATER No dispute reported 06/30/2026 1228807326
Principal investigator 1 PFIZER INC. $4,800.00 11/10/2025 Non-covered Recipient Entity
HEALTHPARTNERS INSTITUTE FOR
AN OPENLABEL RANDOMIZED CONTROLLED PHASE 3 STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB VERSUS CHEMOTHERAPY IN SUBJECTS WITH PREVIOUSLY UNTREATED LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA THAT EXPRESSES HER2 IHC 1 AND GREATER No dispute reported 06/30/2026 1228807852
Principal investigator 1 Astellas Pharma Global Development $2,618.00 11/07/2025 Non-covered Recipient Entity
HEALTHPARTNERS INSTITUTE.
A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer (LUCERNA) No dispute reported 06/30/2026 1234183085
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $4,750.00 11/07/2025 Non-covered Recipient Entity
HEATLHPARTNERS INSTITUTE
EMERGE 402: Phase IV Observational Study to Collect Safety and Outcome Data in Real-World Setting in Adult Patients With Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Zepzelca No dispute reported 06/30/2026 1233739925
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $350.00 11/07/2025 Non-covered Recipient Entity
HEATLHPARTNERS INSTITUTE
EMERGE 402: Phase IV Observational Study to Collect Safety and Outcome Data in Real-World Setting in Adult Patients With Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Zepzelca No dispute reported 06/30/2026 1233739927
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,200.00 11/07/2025 Non-covered Recipient Entity
HEATLHPARTNERS INSTITUTE
EMERGE 402: Phase IV Observational Study to Collect Safety and Outcome Data in Real-World Setting in Adult Patients With Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Zepzelca No dispute reported 06/30/2026 1233739929
Principal investigator 1 ABBVIE INC. $2,400.00 11/06/2025 Non-covered Recipient Entity
HEALTH PARTNERS INSTITUTE
A Study to Assess the Dose Adverse Events and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC) (LIVIGNO-2) No dispute reported 06/30/2026 1202523343
Principal investigator 1 BeOne Medicines Ltd. $525.00 11/05/2025 Non-covered Recipient Entity
HealthPartners Institute
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190329319
Principal investigator 1 BeOne Medicines Ltd. $2,500.00 11/05/2025 Non-covered Recipient Entity
HealthPartners Institute
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190334554
Principal investigator 1 BeOne Medicines Ltd. $500.00 11/05/2025 Non-covered Recipient Entity
HealthPartners Institute
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190334562
Principal investigator 1 BeOne Medicines Ltd. $3,000.00 11/05/2025 Non-covered Recipient Entity
HealthPartners Institute
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190334591
Principal investigator 1 BeOne Medicines Ltd. $1,500.00 11/05/2025 Non-covered Recipient Entity
HealthPartners Institute
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190334595
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $15,098.95 10/28/2025 Non-covered Recipient Entity
Metro Minnesota Community Oncology Research Consortium
A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Luspatercept vs Epoetin Alfa for the Treatment of Anemia Due to Revised International Prognostic Scoring System Very Low, Low, or Intermediate Risk Myelodysplastic Syndrome in Erythropoiesis-Stimulating Agent naive Participants who are Non-Transfusion Dependent No dispute reported 06/30/2026 1235995759
Principal investigator 1 Astellas Pharma Global Development $7,608.00 10/23/2025 Non-covered Recipient Entity
HEALTHPARTNERS INSTITUTE.
A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer (LUCERNA) No dispute reported 06/30/2026 1234183083
Principal investigator 1 PFIZER INC. $32,820.00 10/15/2025 Non-covered Recipient Entity
Metro Minnesota Community Oncology Research Consortium
AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228717005
Principal investigator 1 PFIZER INC. $32,997.51 10/15/2025 Non-covered Recipient Entity
Metro Minnesota Community Oncology Research Consortium
AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228717007
Principal investigator 1 PFIZER INC. $32,997.51 10/15/2025 Non-covered Recipient Entity
Metro Minnesota Community Oncology Research Consortium
AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228718427
Principal investigator 1 PFIZER INC. $32,820.00 10/15/2025 Non-covered Recipient Entity
Metro Minnesota Community Oncology Research Consortium
AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228718667
Principal investigator 1 Genentech, Inc. $992.00 10/09/2025 Non-covered Recipient Entity
HEALTHPARTNERS INSTITUTE
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211612459
Principal investigator 1 AstraZeneca Pharmaceuticals LP $5,185.32 10/08/2025 Non-covered Recipient Entity
HEALTH PARTNERS MINNESOTA
";A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Patients with a germline BRCA mutation and Stage III-IV Ovarian Cancer who are in Complete or Partial Response Following First Line Platinum Based Chemotherapy"; No dispute reported 06/30/2026 1185551553
Principal investigator 1 BeOne Medicines Ltd. $2,220.00 10/08/2025 Non-covered Recipient Entity
HealthPartners Institute
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190334497
Principal investigator 1 PFIZER INC. $42,314.00 10/06/2025 Non-covered Recipient Entity
HEALTHPARTNERS INSTITUTE FOR
AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228807664
Principal investigator 1 Astellas Pharma Global Development $3,250.00 10/03/2025 Non-covered Recipient Entity
HEALTHPARTNERS INSTITUTE.
A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer (LUCERNA) No dispute reported 06/30/2026 1234183075
Principal investigator 1 Astellas Pharma Global Development $3,400.00 10/03/2025 Non-covered Recipient Entity
HEALTHPARTNERS INSTITUTE.
A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer (LUCERNA) No dispute reported 06/30/2026 1234183077
Principal investigator 1 Astellas Pharma Global Development $28,600.00 10/03/2025 Non-covered Recipient Entity
HEALTHPARTNERS INSTITUTE.
A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer (LUCERNA) No dispute reported 06/30/2026 1234183079
Principal investigator 1 Astellas Pharma Global Development $2,500.00 10/03/2025 Non-covered Recipient Entity
HEALTHPARTNERS INSTITUTE.
A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer (LUCERNA) No dispute reported 06/30/2026 1234183081
Principal investigator 1 Servier BioInnovation $1,532.00 10/02/2025 Non-covered Recipient Entity
HEALTHPARTNERS INSTITUTE FOR EDUCATION AND RESEARCH
STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, INDIGO No dispute reported 06/30/2026 1235970214
Principal investigator 1 Genentech, Inc. $992.00 10/01/2025 Non-covered Recipient Entity
HEALTHPARTNERS INSTITUTE
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211612455
Principal investigator 1 PFIZER INC. $2,325.00 09/29/2025 Non-covered Recipient Entity
HEALTHPARTNERS INSTITUTE FOR
A PHASE 2 BASKET STUDY OF DISITAMAB VEDOTIN IN ADULT SUBJECTS WITH PREVIOUSLY TREATED LOCALLYADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS THAT EXPRESS HER2 No dispute reported 06/30/2026 1228824375
Principal investigator 1 Genentech, Inc. $5,192.00 09/25/2025 Non-covered Recipient Entity
Metro Minnesota Community Oncology Research Consortium-MMCOrc
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211625142
Principal investigator 1 PFIZER INC. $21,880.00 09/22/2025 Non-covered Recipient Entity
Metro Minnesota Community Oncology Research Consortium
AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228718423
Principal investigator 1 PFIZER INC. $43,996.68 09/22/2025 Non-covered Recipient Entity
Metro Minnesota Community Oncology Research Consortium
AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228718759
Principal investigator 1 PFIZER INC. $43,996.68 09/19/2025 Non-covered Recipient Entity
Metro Minnesota Community Oncology Research Consortium
AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228716921
Principal investigator 1 PFIZER INC. $21,880.00 09/19/2025 Non-covered Recipient Entity
Metro Minnesota Community Oncology Research Consortium
AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228717103
Principal investigator 1 BeOne Medicines Ltd. $495.00 09/17/2025 Non-covered Recipient Entity
HealthPartners Institute
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190327367
Principal investigator 1 BeOne Medicines Ltd. $236.00 09/12/2025 Non-covered Recipient Entity
HealthPartners Institute
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190343258
Principal investigator 1 Genentech, Inc. $1,984.00 09/04/2025 Non-covered Recipient Entity
HEALTHPARTNERS INSTITUTE
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211612448
Principal investigator 1 PFIZER INC. $54,995.85 09/03/2025 Non-covered Recipient Entity
Metro Minnesota Community Oncology Research Consortium
AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228716745
Principal investigator 1 PFIZER INC. $54,995.85 09/03/2025 Non-covered Recipient Entity
Metro Minnesota Community Oncology Research Consortium
AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228718495
Principal investigator 1 Servier BioInnovation $1,532.00 09/03/2025 Non-covered Recipient Entity
HEALTHPARTNERS INSTITUTE FOR EDUCATION AND RESEARCH
STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, INDIGO No dispute reported 06/30/2026 1235970199
Principal investigator 1 PFIZER INC. $21,998.34 09/02/2025 Non-covered Recipient Entity
Metro Minnesota Community Oncology Research Consortium
AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228718499
Principal investigator 1 PFIZER INC. $21,880.00 09/02/2025 Non-covered Recipient Entity
Metro Minnesota Community Oncology Research Consortium
AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228718502
Principal investigator 1 PFIZER INC. $7,772.88 09/02/2025 Non-covered Recipient Entity
HEALTHPARTNERS INSTITUTE FOR
AN OPENLABEL RANDOMIZED CONTROLLED PHASE 3 STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB VERSUS CHEMOTHERAPY IN SUBJECTS WITH PREVIOUSLY UNTREATED LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA THAT EXPRESSES HER2 IHC 1 AND GREATER No dispute reported 06/30/2026 1228824370
Principal investigator 1 PFIZER INC. $21,880.00 08/30/2025 Non-covered Recipient Entity
Metro Minnesota Community Oncology Research Consortium
AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228716923
Principal investigator 1 PFIZER INC. $21,998.34 08/30/2025 Non-covered Recipient Entity
Metro Minnesota Community Oncology Research Consortium
AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228717105
Principal investigator 1 Genentech, Inc. $26,575.00 08/26/2025 Non-covered Recipient Entity
HEALTH PARTNERS INSTITUTE EDUCATION + RESEARCH
A PHASE III, RANDOMIZED, DOUBLE-BLIND STUDY OF TIRA PLUS ATEZO IN ADJUVANT NSCLC No dispute reported 06/30/2026 1211612359
Principal investigator 1 PFIZER INC. $37,632.15 08/25/2025 Non-covered Recipient Entity
HEALTHPARTNERS INSTITUTE FOR
AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228824416
Principal investigator 1 PFIZER INC. $1,000.00 08/25/2025 Non-covered Recipient Entity
HEALTHPARTNERS INSTITUTE FOR
AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228824422
Principal investigator 1 AstraZeneca Pharmaceuticals LP $21,414.54 08/20/2025 Non-covered Recipient Entity
HEALTH PARTNERS MINNESOTA
a phase 3b,randomized,multicenter,open label study to assess the efficacy of durvalumab plus tremelimumab versus pembrolizumab in combination with platinum based chemotherapy for first line treatment in mtastatic non small cell lung cancer patients with non squamous histology who have mutations and or co mutations in skt11,keap1,or kras triton No dispute reported 06/30/2026 1185551547
Principal investigator 1 PFIZER INC. $35,922.00 08/18/2025 Non-covered Recipient Entity
HEALTHPARTNERS INSTITUTE FOR
AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228826899
Principal investigator 1 PFIZER INC. $4,000.00 08/18/2025 Non-covered Recipient Entity
HEALTHPARTNERS INSTITUTE FOR
AN OPENLABEL RANDOMIZED CONTROLLED PHASE 3 STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB VERSUS CHEMOTHERAPY IN SUBJECTS WITH PREVIOUSLY UNTREATED LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA THAT EXPRESSES HER2 IHC 1 AND GREATER No dispute reported 06/30/2026 1228827627
Principal investigator 1 PFIZER INC. $245.72 08/14/2025 Non-covered Recipient Entity
Metro MN Community Oncology
AN OPENLABEL RANDOMIZED CONTROLLED PHASE 3 STUDY OF SIGVOTATUG VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB COMPARED WITH PEMBROLIZUMAB MONOTHERAPY AS FIRSTLINE TREATMENT IN PARTICIPANTS WITH PDL1 HIGH 50 OF TUMOR CELLS EXPRESSING PDL1 LOCALLY ADVANCED UNRESECTABLE OR METASTATIC NONSMALL CELL LUNG CANCER BE6A LUNG02 No dispute reported 06/30/2026 1228828936
Principal investigator 1 PFIZER INC. $21,880.00 08/12/2025 Non-covered Recipient Entity
Metro Minnesota Community Oncology Research Consortium
AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228717003
Principal investigator 1 PFIZER INC. $21,880.00 08/12/2025 Non-covered Recipient Entity
Metro Minnesota Community Oncology Research Consortium
AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228718757
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $4,089.08 08/07/2025 Non-covered Recipient Entity
Metro Minnesota Community Oncology Research Consortium
A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Luspatercept vs Epoetin Alfa for the Treatment of Anemia Due to Revised International Prognostic Scoring System Very Low, Low, or Intermediate Risk Myelodysplastic Syndrome in Erythropoiesis-Stimulating Agent naive Participants who are Non-Transfusion Dependent No dispute reported 06/30/2026 1235995761
Principal investigator 1 Servier BioInnovation $3,000.00 08/06/2025 Non-covered Recipient Entity
HEALTHPARTNERS INSTITUTE FOR EDUCATION AND RESEARCH
STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, INDIGO No dispute reported 06/30/2026 1235970202
Principal investigator 1 Servier BioInnovation $2,000.00 08/06/2025 Non-covered Recipient Entity
HEALTHPARTNERS INSTITUTE FOR EDUCATION AND RESEARCH
STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, INDIGO No dispute reported 06/30/2026 1235970206
Principal investigator 1 Servier BioInnovation $1,000.00 08/06/2025 Non-covered Recipient Entity
HEALTHPARTNERS INSTITUTE FOR EDUCATION AND RESEARCH
STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, INDIGO No dispute reported 06/30/2026 1235970210
Principal investigator 1 PFIZER INC. $1,683.29 08/04/2025 Non-covered Recipient Entity
HEALTHPARTNERS INSTITUTE FOR
AN OPENLABEL RANDOMIZED CONTROLLED PHASE 3 STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB VERSUS CHEMOTHERAPY IN SUBJECTS WITH PREVIOUSLY UNTREATED LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA THAT EXPRESSES HER2 IHC 1 AND GREATER No dispute reported 06/30/2026 1228826617
Principal investigator 1 PFIZER INC. $610.00 08/04/2025 Non-covered Recipient Entity
HEALTHPARTNERS INSTITUTE FOR
A PHASE 2 BASKET STUDY OF DISITAMAB VEDOTIN IN ADULT SUBJECTS WITH PREVIOUSLY TREATED LOCALLYADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS THAT EXPRESS HER2 No dispute reported 06/30/2026 1228826623
Principal investigator 1 PFIZER INC. $1,000.00 08/04/2025 Non-covered Recipient Entity
HEALTHPARTNERS INSTITUTE FOR
A PHASE 2 BASKET STUDY OF DISITAMAB VEDOTIN IN ADULT SUBJECTS WITH PREVIOUSLY TREATED LOCALLYADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS THAT EXPRESS HER2 No dispute reported 06/30/2026 1228826827
Principal investigator 1 PFIZER INC. $1,000.00 08/04/2025 Non-covered Recipient Entity
HEALTHPARTNERS INSTITUTE FOR
A PHASE 2 BASKET STUDY OF DISITAMAB VEDOTIN IN ADULT SUBJECTS WITH PREVIOUSLY TREATED LOCALLYADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS THAT EXPRESS HER2 No dispute reported 06/30/2026 1228826894
Principal investigator 1 Genentech, Inc. $992.00 07/31/2025 Non-covered Recipient Entity
HEALTHPARTNERS INSTITUTE
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211612451
Principal investigator 1 PFIZER INC. $584.00 07/28/2025 Non-covered Recipient Entity
HEALTHPARTNERS INSTITUTE FOR
A PHASE 2 BASKET STUDY OF DISITAMAB VEDOTIN IN ADULT SUBJECTS WITH PREVIOUSLY TREATED LOCALLYADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS THAT EXPRESS HER2 No dispute reported 06/30/2026 1228807417
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $750.00 07/22/2025 Non-covered Recipient Entity
HEATLHPARTNERS INSTITUTE
EMERGE 402: Phase IV Observational Study to Collect Safety and Outcome Data in Real-World Setting in Adult Patients With Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Zepzelca No dispute reported 06/30/2026 1233739917
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $350.00 07/22/2025 Non-covered Recipient Entity
HEATLHPARTNERS INSTITUTE
EMERGE 402: Phase IV Observational Study to Collect Safety and Outcome Data in Real-World Setting in Adult Patients With Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Zepzelca No dispute reported 06/30/2026 1233739919
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $116.00 07/22/2025 Non-covered Recipient Entity
HEATLHPARTNERS INSTITUTE
EMERGE 402: Phase IV Observational Study to Collect Safety and Outcome Data in Real-World Setting in Adult Patients With Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Zepzelca No dispute reported 06/30/2026 1233739921
Principal investigator 1 PFIZER INC. $21,880.00 07/21/2025 Non-covered Recipient Entity
Metro Minnesota Community Oncology Research Consortium
AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228718823
Principal investigator 1 PFIZER INC. $21,880.00 07/19/2025 Non-covered Recipient Entity
Metro Minnesota Community Oncology Research Consortium
AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228717171
Principal investigator 1 BeOne Medicines Ltd. $1,127.00 07/09/2025 Non-covered Recipient Entity
HealthPartners Institute
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190327381
Principal investigator 1 BeOne Medicines Ltd. $2,816.00 07/09/2025 Non-covered Recipient Entity
HealthPartners Institute
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190331839
Principal investigator 1 BeOne Medicines Ltd. $2,389.00 07/09/2025 Non-covered Recipient Entity
HealthPartners Institute
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190343158
Principal investigator 1 PFIZER INC. $21,998.34 07/07/2025 Non-covered Recipient Entity
Metro Minnesota Community Oncology Research Consortium
AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228718425
Principal investigator 1 PFIZER INC. $8,227.41 07/07/2025 Non-covered Recipient Entity
HEALTHPARTNERS INSTITUTE FOR
AN OPENLABEL RANDOMIZED CONTROLLED PHASE 3 STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB VERSUS CHEMOTHERAPY IN SUBJECTS WITH PREVIOUSLY UNTREATED LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA THAT EXPRESSES HER2 IHC 1 AND GREATER No dispute reported 06/30/2026 1228830079
Principal investigator 1 PFIZER INC. $21,998.34 07/03/2025 Non-covered Recipient Entity
Metro Minnesota Community Oncology Research Consortium
AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228717101
Principal investigator 1 Servier BioInnovation $1,937.00 06/27/2025 Non-covered Recipient Entity
HEALTHPARTNERS INSTITUTE FOR EDUCATION AND RESEARCH
STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, INDIGO No dispute reported 06/30/2026 1235970192
Principal investigator 1 Servier BioInnovation $1,532.00 06/27/2025 Non-covered Recipient Entity
HEALTHPARTNERS INSTITUTE FOR EDUCATION AND RESEARCH
STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, INDIGO No dispute reported 06/30/2026 1235970195
Principal investigator 1 PFIZER INC. $32,820.00 06/23/2025 Non-covered Recipient Entity
Metro Minnesota Community Oncology Research Consortium
AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228823161
Principal investigator 1 Genentech, Inc. $5,530.17 06/09/2025 Non-covered Recipient Entity
MAYO CLINIC ROCHESTER REMIT PROCESSING
Chemo trastuzumab vs chemo trastuzumab pertuzumab No dispute reported 06/30/2026 1211622940
Principal investigator 1 PFIZER INC. $63,610.00 06/09/2025 Non-covered Recipient Entity
HEALTHPARTNERS INSTITUTE FOR
AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228830054
Principal investigator 1 PFIZER INC. $41,324.70 06/09/2025 Non-covered Recipient Entity
HEALTHPARTNERS INSTITUTE FOR
AN OPENLABEL RANDOMIZED CONTROLLED PHASE 3 STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB VERSUS CHEMOTHERAPY IN SUBJECTS WITH PREVIOUSLY UNTREATED LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA THAT EXPRESSES HER2 IHC 1 AND GREATER No dispute reported 06/30/2026 1228830061
Principal investigator 1 AstraZeneca UK Limited $25,220.74 05/30/2025 Non-covered Recipient Entity
HEALTH PARTNERS MINNESOTA
CAMBRIA-2 A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease No dispute reported 06/30/2026 1185551549
Principal investigator 1 PFIZER INC. $54,995.85 05/29/2025 Non-covered Recipient Entity
Metro Minnesota Community Oncology Research Consortium
AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228827008
Principal investigator 1 PFIZER INC. $54,995.85 05/28/2025 Non-covered Recipient Entity
Metro Minnesota Community Oncology Research Consortium
AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228822488
Principal investigator 1 PFIZER INC. $5,358.45 05/28/2025 Non-covered Recipient Entity
HEALTHPARTNERS INSTITUTE FOR
AN OPENLABEL RANDOMIZED CONTROLLED PHASE 3 STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB VERSUS CHEMOTHERAPY IN SUBJECTS WITH PREVIOUSLY UNTREATED LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA THAT EXPRESSES HER2 IHC 1 AND GREATER No dispute reported 06/30/2026 1228829481
Principal investigator 1 PFIZER INC. $4,020.47 05/28/2025 Non-covered Recipient Entity
HEALTHPARTNERS INSTITUTE FOR
AN OPENLABEL RANDOMIZED CONTROLLED PHASE 3 STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB VERSUS CHEMOTHERAPY IN SUBJECTS WITH PREVIOUSLY UNTREATED LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA THAT EXPRESSES HER2 IHC 1 AND GREATER No dispute reported 06/30/2026 1228832759
Principal investigator 1 PFIZER INC. $2,325.00 05/28/2025 Non-covered Recipient Entity
HEALTHPARTNERS INSTITUTE FOR
AN OPENLABEL RANDOMIZED CONTROLLED PHASE 3 STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB VERSUS CHEMOTHERAPY IN SUBJECTS WITH PREVIOUSLY UNTREATED LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA THAT EXPRESSES HER2 IHC 1 AND GREATER No dispute reported 06/30/2026 1228832778
Principal investigator 1 PFIZER INC. $7,807.63 05/28/2025 Non-covered Recipient Entity
HEALTHPARTNERS INSTITUTE FOR
AN OPENLABEL RANDOMIZED CONTROLLED PHASE 3 STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB VERSUS CHEMOTHERAPY IN SUBJECTS WITH PREVIOUSLY UNTREATED LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA THAT EXPRESSES HER2 IHC 1 AND GREATER No dispute reported 06/30/2026 1228833316
Principal investigator 1 PFIZER INC. $32,820.00 05/20/2025 Non-covered Recipient Entity
Metro Minnesota Community Oncology Research Consortium
AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228826587
Principal investigator 1 PFIZER INC. $32,820.00 05/19/2025 Non-covered Recipient Entity
Metro Minnesota Community Oncology Research Consortium
AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228822493
Principal investigator 1 BeiGene, Ltd. $2,389.00 05/16/2025 Non-covered Recipient Entity
HealthPartners Institute
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190320826
Principal investigator 1 BeiGene, Ltd. $1,127.00 05/16/2025 Non-covered Recipient Entity
HealthPartners Institute
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190325078
Principal investigator 1 PFIZER INC. $87,993.36 05/12/2025 Non-covered Recipient Entity
Metro Minnesota Community Oncology Research Consortium
AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228827243
Principal investigator 1 AstraZeneca UK Limited $9,200.00 05/07/2025 Non-covered Recipient Entity
HEALTH PARTNERS MINNESOTA
A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Docetaxel Versus Placebo + Docetaxel as Treatment for Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) No dispute reported 06/30/2026 1185551551
Principal investigator 1 Genentech, Inc. $3,500.00 05/06/2025 Non-covered Recipient Entity
Metro Minnesota Community Oncology Research Consortium-MMCOrc
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211625134
Principal investigator 1 Genentech, Inc. $4,288.00 05/06/2025 Non-covered Recipient Entity
Metro Minnesota Community Oncology Research Consortium-MMCOrc
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211625139
Principal investigator 1 PFIZER INC. $87,993.36 05/05/2025 Non-covered Recipient Entity
Metro Minnesota Community Oncology Research Consortium
AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228823294
Principal investigator 1 PFIZER INC. $3,100.00 05/05/2025 Non-covered Recipient Entity
HEALTHPARTNERS INSTITUTE FOR
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228832765
Principal investigator 1 BeiGene, Ltd. $1,551.00 04/25/2025 Non-covered Recipient Entity
HealthPartners Institute
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190320778
Principal investigator 1 BeiGene, Ltd. $2,000.00 04/25/2025 Non-covered Recipient Entity
HealthPartners Institute
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190320806
Principal investigator 1 BeiGene, Ltd. $2,389.00 04/25/2025 Non-covered Recipient Entity
HealthPartners Institute
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190322918
Principal investigator 1 BeiGene, Ltd. $2,002.00 04/25/2025 Non-covered Recipient Entity
HealthPartners Institute
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190322940
Principal investigator 1 BeiGene, Ltd. $470.00 04/21/2025 Non-covered Recipient Entity
HealthPartners Institute
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190320844
Principal investigator 1 PFIZER INC. $30,092.25 04/21/2025 Non-covered Recipient Entity
HEALTHPARTNERS INSTITUTE FOR
AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228832720
Principal investigator 1 PFIZER INC. $10,940.00 04/16/2025 Non-covered Recipient Entity
Metro Minnesota Community Oncology Research Consortium
AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228827693
Principal investigator 1 Genentech, Inc. $1,984.00 04/15/2025 Non-covered Recipient Entity
HEALTHPARTNERS INSTITUTE
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211612440
Principal investigator 1 PFIZER INC. $10,940.00 04/15/2025 Non-covered Recipient Entity
Metro Minnesota Community Oncology Research Consortium
AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228823253
Principal investigator 1 PFIZER INC. $15,000.00 04/14/2025 Non-covered Recipient Entity
HEALTHPARTNERS INSTITUTE FOR
A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH TRASTUZUMAB AND PERTUZUMAB AS MAINTENANCE THERAPY FOR METASTATIC HER2 BREAST CANCER HER2CLIMB05 No dispute reported 06/30/2026 1228833410
Principal investigator 1 PFIZER INC. $54,995.85 04/11/2025 Non-covered Recipient Entity
Metro Minnesota Community Oncology Research Consortium
AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228826581
Principal investigator 1 PFIZER INC. $54,995.85 04/10/2025 Non-covered Recipient Entity
Metro Minnesota Community Oncology Research Consortium
AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228822429
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $931.50 04/08/2025 Non-covered Recipient Entity
HEATLHPARTNERS INSTITUTE
EMERGE 402: Phase IV Observational Study to Collect Safety and Outcome Data in Real-World Setting in Adult Patients With Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Zepzelca No dispute reported 06/30/2026 1233739915
Principal investigator 1 PFIZER INC. $580.00 04/07/2025 Non-covered Recipient Entity
HEALTHPARTNERS INSTITUTE FOR
AN OPENLABEL RANDOMIZED CONTROLLED PHASE 3 STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB VERSUS CHEMOTHERAPY IN SUBJECTS WITH PREVIOUSLY UNTREATED LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA THAT EXPRESSES HER2 IHC 1 AND GREATER No dispute reported 06/30/2026 1228832744
Principal investigator 1 PFIZER INC. $8,100.00 04/07/2025 Non-covered Recipient Entity
HEALTHPARTNERS INSTITUTE FOR
AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228832868
Principal investigator 1 PFIZER INC. $1,000.00 04/07/2025 Non-covered Recipient Entity
HEALTHPARTNERS INSTITUTE FOR
AN OPENLABEL RANDOMIZED CONTROLLED PHASE 3 STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB VERSUS CHEMOTHERAPY IN SUBJECTS WITH PREVIOUSLY UNTREATED LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA THAT EXPRESSES HER2 IHC 1 AND GREATER No dispute reported 06/30/2026 1228832943
Principal investigator 1 PFIZER INC. $37,282.00 04/07/2025 Non-covered Recipient Entity
HEALTHPARTNERS INSTITUTE FOR
AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228833321
Principal investigator 1 PFIZER INC. $2,532.58 04/07/2025 Non-covered Recipient Entity
HEALTHPARTNERS INSTITUTE FOR
AN OPENLABEL RANDOMIZED CONTROLLED PHASE 3 STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB VERSUS CHEMOTHERAPY IN SUBJECTS WITH PREVIOUSLY UNTREATED LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA THAT EXPRESSES HER2 IHC 1 AND GREATER No dispute reported 06/30/2026 1228833469
Principal investigator 1 Mirati Therapeutics, Inc. $91,532.25 04/04/2025 Non-covered Recipient Entity
Healthpartners Institute
A Phase 2 Trial of Combination Therapies With Adagrasib in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutatio No dispute reported 06/30/2026 1236531095
Principal investigator 1 PFIZER INC. $65,995.02 04/01/2025 Non-covered Recipient Entity
Metro Minnesota Community Oncology Research Consortium
AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228826569
Principal investigator 1 PFIZER INC. $128.00 03/31/2025 Non-covered Recipient Entity
HEALTHPARTNERS INSTITUTE FOR
A PHASE 2 BASKET STUDY OF DISITAMAB VEDOTIN IN ADULT SUBJECTS WITH PREVIOUSLY TREATED LOCALLYADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS THAT EXPRESS HER2 No dispute reported 06/30/2026 1228833356
Principal investigator 1 Servier BioInnovation $1,937.00 03/31/2025 Non-covered Recipient Entity
HEALTHPARTNERS INSTITUTE FOR EDUCATION AND RESEARCH
STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, INDIGO No dispute reported 06/30/2026 1235970184
Principal investigator 1 Servier BioInnovation $1,532.00 03/31/2025 Non-covered Recipient Entity
HEALTHPARTNERS INSTITUTE FOR EDUCATION AND RESEARCH
STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, INDIGO No dispute reported 06/30/2026 1235970188
Principal investigator 1 Novartis Pharmaceuticals Corporation $261,091.59 03/24/2025 Covered Recipient Teaching Hospital
Regions Hospital
A Phase IIIb, Multi-center, Open-label, Randomized Study of Tolerability and Efficacy of Oral Asciminib Versus Nilotinib in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase No dispute reported 06/30/2026 1190297083
Principal investigator 1 PFIZER INC. $65,995.02 03/19/2025 Non-covered Recipient Entity
Metro Minnesota Community Oncology Research Consortium
AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228823242
Principal investigator 1 BeiGene, Ltd. $2,389.00 03/12/2025 Non-covered Recipient Entity
HealthPartners Institute
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190320032
Principal investigator 1 BeiGene, Ltd. $2,816.00 03/12/2025 Non-covered Recipient Entity
HealthPartners Institute
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190320034
Principal investigator 1 BeiGene, Ltd. $2,389.00 03/12/2025 Non-covered Recipient Entity
HealthPartners Institute
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190324236
Principal investigator 1 PFIZER INC. $36,800.00 03/10/2025 Non-covered Recipient Entity
HEALTHPARTNERS INSTITUTE FOR
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228832725
Principal investigator 1 PFIZER INC. $1,000.00 03/10/2025 Non-covered Recipient Entity
HEALTHPARTNERS INSTITUTE FOR
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228832845
Principal investigator 1 PFIZER INC. $770.00 03/03/2025 Non-covered Recipient Entity
HEALTHPARTNERS INSTITUTE FOR
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228833423
Principal investigator 1 BeiGene, Ltd. $1,000.00 02/28/2025 Non-covered Recipient Entity
HealthPartners Institute
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190324218
Principal investigator 1 BeiGene, Ltd. $1,380.00 02/28/2025 Non-covered Recipient Entity
HealthPartners Institute
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190324272
Principal investigator 1 BeiGene, Ltd. $257.00 02/28/2025 Non-covered Recipient Entity
HealthPartners Institute
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190324612
Principal investigator 1 BeiGene, Ltd. $2,389.00 02/21/2025 Non-covered Recipient Entity
HealthPartners Institute
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190324222
Principal investigator 1 BeiGene, Ltd. $2,389.00 02/21/2025 Non-covered Recipient Entity
HealthPartners Institute
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190324336
Principal investigator 1 BeiGene, Ltd. $2,389.00 02/21/2025 Non-covered Recipient Entity
HealthPartners Institute
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190324354
Principal investigator 1 BeiGene, Ltd. $1,127.00 02/21/2025 Non-covered Recipient Entity
HealthPartners Institute
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190324380
Principal investigator 1 BeiGene, Ltd. $2,389.00 02/21/2025 Non-covered Recipient Entity
HealthPartners Institute
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190324616
Principal investigator 1 Celgene Corporation $5,847.55 02/21/2025 Non-covered Recipient Entity
Healthpartners Institute For Education And Research
A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) vs Epoetin Alfa for the Treatment of Anemia Due to Revised International Prognostic Scoring System (IPSS-R) Very Low, Low, or Intermediate Risk Myelodysplastic Syndrome (MDS) in Erythropoiesis-Stimulating Agent (ESA)-naive Participants who are Non-Transfusion Dependent (NTD): The ELEMENT-MDS Trial No dispute reported 06/30/2026 1222305614
Principal investigator 1 ABBVIE INC. $8,000.00 02/20/2025 Non-covered Recipient Entity
HEALTH PARTNERS INSTITUTE
M24-052 - A Study to Assess the Dose Adverse Events and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC) (LIVIGNO-2) No dispute reported 06/30/2026 1202453217
Principal investigator 1 PFIZER INC. $1,246.00 02/18/2025 Non-covered Recipient Entity
HEALTHPARTNERS INSTITUTE FOR
A PHASE 2 BASKET STUDY OF DISITAMAB VEDOTIN IN ADULT SUBJECTS WITH PREVIOUSLY TREATED LOCALLYADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS THAT EXPRESS HER2 No dispute reported 06/30/2026 1228832755
Principal investigator 1 PFIZER INC. $1,507.00 02/18/2025 Non-covered Recipient Entity
HEALTHPARTNERS INSTITUTE FOR
A PHASE 2 BASKET STUDY OF DISITAMAB VEDOTIN IN ADULT SUBJECTS WITH PREVIOUSLY TREATED LOCALLYADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS THAT EXPRESS HER2 No dispute reported 06/30/2026 1228833403
Principal investigator 1 PFIZER INC. $4,000.00 02/18/2025 Non-covered Recipient Entity
HEALTHPARTNERS INSTITUTE FOR
A PHASE 2 BASKET STUDY OF DISITAMAB VEDOTIN IN ADULT SUBJECTS WITH PREVIOUSLY TREATED LOCALLYADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS THAT EXPRESS HER2 No dispute reported 06/30/2026 1228833434
Principal investigator 1 Genentech, Inc. $12,000.00 02/17/2025 Non-covered Recipient Entity
Metro Minnesota Community Oncology Research Consortium-MMCOrc
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211625121
Principal investigator 1 Genentech, Inc. $1,984.00 02/11/2025 Non-covered Recipient Entity
HEALTHPARTNERS INSTITUTE
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211612444
Principal investigator 1 PFIZER INC. $14,138.55 02/10/2025 Non-covered Recipient Entity
HEALTHPARTNERS INSTITUTE FOR
AN OPENLABEL RANDOMIZED CONTROLLED PHASE 3 STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB VERSUS CHEMOTHERAPY IN SUBJECTS WITH PREVIOUSLY UNTREATED LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA THAT EXPRESSES HER2 IHC 1 AND GREATER No dispute reported 06/30/2026 1228833452
Principal investigator 1 PFIZER INC. $54,995.85 02/06/2025 Non-covered Recipient Entity
Metro Minnesota Community Oncology Research Consortium
AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228827122
Principal investigator 1 Novartis Pharmaceuticals Corporation $10,903.76 02/04/2025 Non-covered Recipient Entity
INTERIM HEALTH CARE
A Phase IIIb, Multi-center, Open-label, Randomized Study of Tolerability and Efficacy of Oral Asciminib Versus Nilotinib in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase No dispute reported 06/30/2026 1190309750
Principal investigator 1 BeiGene, Ltd. $1,000.00 02/03/2025 Non-covered Recipient Entity
HealthPartners Institute
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190320116
Principal investigator 1 BeiGene, Ltd. $1,000.00 02/03/2025 Non-covered Recipient Entity
HealthPartners Institute
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190320122
Principal investigator 1 PFIZER INC. $54,995.85 02/03/2025 Non-covered Recipient Entity
Metro Minnesota Community Oncology Research Consortium
AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228823155
Principal investigator 1 PFIZER INC. $5,658.00 02/03/2025 Non-covered Recipient Entity
HEALTHPARTNERS INSTITUTE FOR
A PHASE 2 BASKET STUDY OF DISITAMAB VEDOTIN IN ADULT SUBJECTS WITH PREVIOUSLY TREATED LOCALLYADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS THAT EXPRESS HER2 No dispute reported 06/30/2026 1228832802
Principal investigator 1 PFIZER INC. $820.00 02/03/2025 Non-covered Recipient Entity
HEALTHPARTNERS INSTITUTE FOR
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228833327
Principal investigator 1 Genentech, Inc. $3,601.00 01/30/2025 Non-covered Recipient Entity
Metro Minnesota Community Oncology Research Consortium-MMCOrc
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211625124
Principal investigator 1 Genentech, Inc. $237.00 01/30/2025 Non-covered Recipient Entity
Metro Minnesota Community Oncology Research Consortium-MMCOrc
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211625127
Principal investigator 1 BeiGene, Ltd. $2,389.00 01/29/2025 Non-covered Recipient Entity
HealthPartners Institute
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190324260
Principal investigator 1 Celgene Corporation $24,842.15 01/29/2025 Non-covered Recipient Entity
Healthpartners Institute For Education And Research
A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) vs Epoetin Alfa for the Treatment of Anemia Due to Revised International Prognostic Scoring System (IPSS-R) Very Low, Low, or Intermediate Risk Myelodysplastic Syndrome (MDS) in Erythropoiesis-Stimulating Agent (ESA)-naive Participants who are Non-Transfusion Dependent (NTD): The ELEMENT-MDS Trial No dispute reported 06/30/2026 1222305564
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $621.00 01/29/2025 Non-covered Recipient Entity
HEATLHPARTNERS INSTITUTE
EMERGE 402: Phase IV Observational Study to Collect Safety and Outcome Data in Real-World Setting in Adult Patients With Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Zepzelca No dispute reported 06/30/2026 1233739913
Principal investigator 1 BeiGene, Ltd. $695.00 01/27/2025 Non-covered Recipient Entity
HealthPartners Institute
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190324372
Principal investigator 1 Servier BioInnovation $1,532.00 01/17/2025 Non-covered Recipient Entity
HEALTHPARTNERS INSTITUTE FOR EDUCATION AND RESEARCH
STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, INDIGO No dispute reported 06/30/2026 1235970178
Principal investigator 1 Servier BioInnovation $1,532.00 01/17/2025 Non-covered Recipient Entity
HEALTHPARTNERS INSTITUTE FOR EDUCATION AND RESEARCH
STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, INDIGO No dispute reported 06/30/2026 1235970181
Principal investigator 1 Genentech, Inc. $128.00 01/09/2025 Non-covered Recipient Entity
Metro Minnesota Community Oncology Research Consortium-MMCOrc
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211625130
Principal investigator 1 Novartis Pharmaceuticals Corporation $12,297.50 01/09/2025 Non-covered Recipient Entity
METROPOLITAN MINNESOTA CCOP
Ribociclib Standard Endocrine therapy in patients with HR HER2 Early BC at High amp Intermediate Risk for Recurrence No dispute reported 06/30/2026 1190306477
Principal investigator 1 Novartis Pharmaceuticals Corporation $7,768.08 01/09/2025 Non-covered Recipient Entity
METROPOLITAN MINNESOTA CCOP
A Phase III, Randomized, Double-blind Study of Ianalumab (VAY736) Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (VAYHIT1) No dispute reported 06/30/2026 1190306479
Principal investigator 1 PFIZER INC. $65,995.02 01/09/2025 Non-covered Recipient Entity
Metro Minnesota Community Oncology Research Consortium
AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228827118
Principal investigator 1 Merck Sharp & Dohme LLC $2,500.00 01/06/2025 Non-covered Recipient Entity
Regions Hospital
A Phase 4, single-arm, open-label clinical study of pembrolizumab MK-3475 to evaluate the efficacy and safety of MK-3475 plus carboplatin and paclitaxel as first-line treatment of recurrent,metastatic head and neck squamous cell carcinoma KEYNOTE-B10 No dispute reported 06/30/2026 1232927957
Principal investigator 1 PFIZER INC. $65,995.02 01/02/2025 Non-covered Recipient Entity
Metro Minnesota Community Oncology Research Consortium
AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228823247